跳转至内容
Merck
CN

270253

4-羟基苯甲酰胺

98%

登录 查看组织和合同定价。

选择尺寸


关于此项目

线性分子式:
HOC6H4CONH2
化学文摘社编号:
分子量:
137.14
NACRES:
NA.22
PubChem Substance ID:
UNSPSC Code:
12352100
EC Number:
210-602-7
MDL number:
Assay:
98%
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

InChI key

QXSAKPUBHTZHKW-UHFFFAOYSA-N

InChI

1S/C7H7NO2/c8-7(10)5-1-3-6(9)4-2-5/h1-4,9H,(H2,8,10)

SMILES string

NC(=O)c1ccc(O)cc1

assay

98%

mp

161-162 °C (lit.)

functional group

amide

Quality Level

General description

通过微燃烧或大燃烧量热法对4-羟基苯甲酰胺形成的标准摩尔焓进行了研究

Application

4-羟基苯甲酰胺已被用于合成balanol,一种有效的蛋白激酶C(PKC)抑制剂

wgk

WGK 3

pictograms

Exclamation mark

signalword

Warning

Hazard Classifications

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

target_organs

Respiratory system

存储类别

11 - Combustible Solids

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves

法规信息

新产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

C Emoto et al.
Xenobiotica; the fate of foreign compounds in biological systems, 37(12), 1408-1420 (2007-10-19)
CJ-036878, N-(3-phenethoxybenzyl)-4-hydroxybenzamide, was developed as an antagonist of the N-methyl-D-aspartate receptor NR2B subunit. Two dimeric metabolites, CJ-047710 and CJ-047713, were identified from the incubation mixture with CJ-036878 in human liver microsomes (HLM). The identification of the enzymes involved in the
G D Hartman et al.
Bioorganic & medicinal chemistry letters, 9(6), 863-868 (1999-04-17)
A new series of potent, linearly-minimized, orally active, selective GPIIb/IIIa inhibitors is identified. Thus 15 (L-750,034) achieves interaction via a constrained, non-turned conformation that maintains the proper distance between its charged termini and full sulfonamide exosite interaction. The diminutive stature
H Nishida et al.
Xenobiotica; the fate of foreign compounds in biological systems, 37(12), 1394-1407 (2007-11-23)
The identification of metabolites in the early stages of drug discovery is important not only for guiding structure-activity relationships (SAR) and structure-metabolism relationships (SMR) strategies, but also for predicting the potential for adverse events. The present study investigated the phase
R S Randad et al.
Bioorganic & medicinal chemistry, 4(9), 1471-1480 (1996-09-01)
A combination of structure-activity studies, kinetic analysis, X-ray crystallographic analysis, and modeling were employed in the design of a novel series of HIV-1 protease (HIV PR) inhibitors. The crystal structure of a complex of HIV PR with SRSS-2,5-bis[N-(tert-butyloxycarbonyl)amino]-3,4-dihydroxy-1, 6-diphenylhexane (1)
Alex N Manin et al.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 65, 56-64 (2014-09-15)
The main problem occurring at the early stages of cocrystal search is the choice of an effective screening technique. Among the most popular techniques of obtaining cocrystals are crystallization from solution, crystallization from melt and solvent-drop grinding. This paper represents

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持